Table 1.

Demographics and clinical characteristics for study subjects (n = 69 eyes)

Characteristics	Value
Age	52.49 ± 14.10
Sex (female: male)	36: 33
Laterality (right: left)	18: 51
Axial length (mm)	24.44 ± 1.37
Anterior chamber depth (mm)	3.40 ± 0.37
Spherical equivalent (diopter)	−1.71 ± 2.57
IOP (mmHg)
Baseline	17.9 ± 3.8
After 1 mon	14.6 ± 2.8
After 3 mon	14.2 ± 3.0
After 6 mon	14.6 ± 3.1
After 9 mon	14.4 ± 2.9
After 1 yr	14.3 ± 3.0
Post-medication average IOP*	14.4 ± 2.7
Post-medication IOP SD†	1.4 ± 0.8
Post-medication IOP range‡	2.9 ± 1.7
Mean IOP reduction§	3.5 ± 2.1
Percentage mean IOP reduction (%)	18.76 ± 9.03
Mean deviation (dB)	−4.44 ± 4.04
Visual field index (%)	91.22 ± 10.36
Average retinal nerve fiber layer thickness (μm)	82.64 ± 14.70
Medications
Prostaglandin analogues	40
FDCD (carbonic anhydrase inhibitor & beta blocker)	24
FDCD (prostaglandin & beta blocker)	3
Alpha agonist	2

Values are presented as mean ± SD or number.

IOP = intraocular pressure; SD = standard deviation; FDCD = fixed-dose combination drug.

^*Defined as the mean value of IOPs at 1, 3, 6, 9 months and 1 year;

^†Defined as the SD of the mean IOP within of IOPs at 1, 3, 6, 9 months and 1 year;

^‡Calculated as the difference between maximum and minimum IOP values after using IOP-lowering medication;

^§Calculated by subtracting the post average IOP from the baseline IOP.